Brokerages Set IDEXX Laboratories, Inc. (NASDAQ:IDXX) PT at $783.33

IDEXX Laboratories, Inc. (NASDAQ:IDXX) has earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $783.3333.

A number of analysts have commented on the company. UBS Group decreased their price objective on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a report on Tuesday, February 3rd. Piper Sandler dropped their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Barclays dropped their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Finally, BTIG Research dropped their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $575.72 on Thursday. IDEXX Laboratories has a 12-month low of $356.14 and a 12-month high of $769.98. The business’s fifty day moving average is $637.24 and its 200 day moving average is $663.15. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The stock has a market cap of $45.78 billion, a P/E ratio of 44.05, a P/E/G ratio of 3.46 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Sell-side analysts anticipate that IDEXX Laboratories will post 11.93 earnings per share for the current fiscal year.

Insider Activity

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of the stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the transaction, the executive vice president owned 9,823 shares in the company, valued at $6,352,730.56. This trade represents a 53.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of IDEXX Laboratories stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the completion of the transaction, the chief executive officer owned 83,606 shares of the company’s stock, valued at $54,975,125.30. The trade was a 21.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 45,957 shares of company stock valued at $29,862,109. 0.98% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On IDEXX Laboratories

Several hedge funds have recently made changes to their positions in the stock. Blalock Williams LLC purchased a new stake in IDEXX Laboratories in the 3rd quarter worth approximately $590,000. New York State Common Retirement Fund grew its position in shares of IDEXX Laboratories by 6.8% during the 3rd quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock valued at $38,477,000 after purchasing an additional 3,820 shares in the last quarter. Mediolanum International Funds Ltd grew its position in shares of IDEXX Laboratories by 14.5% during the 3rd quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock valued at $24,441,000 after purchasing an additional 4,909 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of IDEXX Laboratories by 16.7% in the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock worth $840,638,000 after purchasing an additional 187,967 shares during the period. Finally, Orion Porfolio Solutions LLC raised its position in shares of IDEXX Laboratories by 116.6% in the second quarter. Orion Porfolio Solutions LLC now owns 10,718 shares of the company’s stock worth $5,749,000 after buying an additional 5,770 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.